Molecular pathogenesis of pulmonary arterial hypertension.

Recent investigations have suggested that it might be possible to reverse the pathology of pulmonary arterial hypertension (PAH), a disorder that can be rapidly progressive and fatal despite current treatments including i.v. prostacyclin. This review will address the cellular and molecular processes implicated in clinical, genetic, and experimental studies as underlying the pulmonary vascular abnormalities associated with PAH. Emerging treatments are aimed at inducing apoptosis of abnormal vascular cells that obstruct blood flow and at promoting regeneration of "lost" distal vasculature.

[1]  Dave P. Miller,et al.  Characterization of connective tissue disease-associated pulmonary arterial hypertension from REVEAL: identifying systemic sclerosis as a unique phenotype. , 2010, Chest.

[2]  M. Varella‐Garcia,et al.  Somatic chromosome abnormalities in the lungs of patients with pulmonary arterial hypertension. , 2010, American journal of respiratory and critical care medicine.

[3]  P. Lehner,et al.  Identification of a Lysosomal Pathway Regulating Degradation of the Bone Morphogenetic Protein Receptor Type II , 2010, The Journal of Biological Chemistry.

[4]  G. Butrous,et al.  Schistosomiasis-induced experimental pulmonary hypertension: role of interleukin-13 signaling. , 2010, The American journal of pathology.

[5]  G. Lopaschuk,et al.  Fatty Acid Oxidation and Malonyl-CoA Decarboxylase in the Vascular Remodeling of Pulmonary Hypertension , 2010, Science Translational Medicine.

[6]  Gene Kim,et al.  Epigenetic Attenuation of Mitochondrial Superoxide Dismutase 2 in Pulmonary Arterial Hypertension: A Basis for Excessive Cell Proliferation and a New Therapeutic Target , 2010, Circulation.

[7]  Y. E. Chen,et al.  Covalent peroxisome proliferator-activated receptor gamma adduction by nitro-fatty acids: selective ligand activity and anti-diabetic signaling actions. , 2010, The Journal of biological chemistry.

[8]  R. Khanin,et al.  Dynamic Changes in Lung MicroRNA Profiles During the Development of Pulmonary Hypertension due to Chronic Hypoxia and Monocrotaline , 2010, Arteriosclerosis, thrombosis, and vascular biology.

[9]  E. Morrisey,et al.  The von Hippel-Lindau Chuvash mutation promotes pulmonary hypertension and fibrosis in mice. , 2010, The Journal of clinical investigation.

[10]  M. Gladwin,et al.  Nitrite Potently Inhibits Hypoxic and Inflammatory Pulmonary Arterial Hypertension and Smooth Muscle Proliferation via Xanthine Oxidoreductase–Dependent Nitric Oxide Generation , 2010, Circulation.

[11]  G. Hansmann,et al.  Tie2-mediated loss of peroxisome proliferator-activated receptor-gamma in mice causes PDGF receptor-beta-dependent pulmonary arterial muscularization. , 2009, American journal of physiology. Lung cellular and molecular physiology.

[12]  N. Voelkel,et al.  Endothelial cells and pulmonary arterial hypertension: apoptosis, proliferation, interaction and transdifferentiation , 2009, Respiratory research.

[13]  J. Cogan,et al.  Penetrance of pulmonary arterial hypertension is modulated by the expression of normal BMPR2 allele , 2009, Human mutation.

[14]  R. Johns,et al.  Resistin-like molecule-beta in scleroderma-associated pulmonary hypertension. , 2009, American journal of respiratory cell and molecular biology.

[15]  N. Morrell,et al.  Altered Bone Morphogenetic Protein and Transforming Growth Factor-β Signaling in Rat Models of Pulmonary Hypertension: Potential for Activin Receptor-Like Kinase-5 Inhibition in Prevention and Progression of Disease , 2009, Circulation.

[16]  E. Mark,et al.  Interleukin-6 Overexpression Induces Pulmonary Hypertension , 2009, Circulation research.

[17]  J. Axelrod,et al.  Bone morphogenetic protein 2 induces pulmonary angiogenesis via Wnt–β-catenin and Wnt–RhoA–Rac1 pathways , 2009, The Journal of cell biology.

[18]  G. Hansmann,et al.  Insulin resistance in pulmonary arterial hypertension , 2008, European Respiratory Journal.

[19]  M. Majesky,et al.  A sonic hedgehog signaling domain in the arterial adventitia supports resident Sca1+ smooth muscle progenitor cells , 2008, Proceedings of the National Academy of Sciences.

[20]  A. Harmar,et al.  Converging Evidence in Support of the Serotonin Hypothesis of Dexfenfluramine-Induced Pulmonary Hypertension With Novel Transgenic Mice , 2008, Circulation.

[21]  R. Trembath,et al.  Mutations in Bone Morphogenetic Protein Type II Receptor Cause Dysregulation of Id Gene Expression in Pulmonary Artery Smooth Muscle Cells: Implications for Familial Pulmonary Arterial Hypertension , 2008, Circulation research.

[22]  G. Hansmann,et al.  An antiproliferative BMP-2/PPARgamma/apoE axis in human and murine SMCs and its role in pulmonary hypertension. , 2008, The Journal of clinical investigation.

[23]  Alireza Afshari,et al.  Indoor particles affect vascular function in the aged: an air filtration-based intervention study. , 2008, American journal of respiratory and critical care medicine.

[24]  V. Kurup,et al.  Pulmonary arterial remodeling induced by a Th2 immune response , 2008, The Journal of experimental medicine.

[25]  N. Ambartsumian,et al.  Reactivation of gammaHV68 induces neointimal lesions in pulmonary arteries of S100A4/Mts1-overexpressing mice in association with degradation of elastin. , 2008, American journal of physiology. Lung cellular and molecular physiology.

[26]  David Evans,et al.  Evidence of a role for osteoprotegerin in the pathogenesis of pulmonary arterial hypertension. , 2008, The American journal of pathology.

[27]  N. Ambartsumian,et al.  Reactivation of HV 68 induces neointimal lesions in pulmonary arteries of S 100 A 4 / Mts 1-overexpressing mice in association with degradation of elastin , 2008 .

[28]  A. Hata,et al.  SMAD proteins control DROSHA-mediated microRNA maturation , 2008, Nature.

[29]  S. Rich,et al.  A USA-based registry for pulmonary arterial hypertension: 1982–2006 , 2007, European Respiratory Journal.

[30]  S. Erzurum,et al.  Hyperproliferative apoptosis-resistant endothelial cells in idiopathic pulmonary arterial hypertension. , 2007, American journal of physiology. Lung cellular and molecular physiology.

[31]  Yingling Liu,et al.  The 5‐HT transporter transactivates the PDGFβ receptor in pulmonary artery smooth muscle cells , 2007 .

[32]  E. Bruyneel,et al.  Proinvasive activity of BMP-7 through SMAD4/src-independent and ERK/Rac/JNK-dependent signaling pathways in colon cancer cells. , 2007, Cellular signalling.

[33]  S. Archer,et al.  The nuclear factor of activated T cells in pulmonary arterial hypertension can be therapeutically targeted , 2007, Proceedings of the National Academy of Sciences.

[34]  N. Voelkel,et al.  Absence of T cells confers increased pulmonary arterial hypertension and vascular remodeling. , 2007, American journal of respiratory and critical care medicine.

[35]  H. Champion,et al.  Right ventricular failure complicating heart failure: Pathophysiology, significance, and management strategies , 2007, Current cardiology reports.

[36]  M. Humbert,et al.  Fractalkine-induced smooth muscle cell proliferation in pulmonary hypertension , 2007, European Respiratory Journal.

[37]  D. Curiel,et al.  Bone morphogenetic protein type 2 receptor gene therapy attenuates hypoxic pulmonary hypertension. , 2007, American journal of physiology. Lung cellular and molecular physiology.

[38]  A. Zernecke,et al.  Chemokines in vascular remodeling , 2007, Thrombosis and Haemostasis.

[39]  P. Insel,et al.  Pulmonary artery smooth muscle cells from normal subjects and IPAH patients show divergent cAMP-mediated effects on TRPC expression and capacitative Ca2+ entry. , 2007, American journal of physiology. Lung cellular and molecular physiology.

[40]  K. Stenmark,et al.  Rosiglitazone attenuates hypoxia-induced pulmonary arterial remodeling. , 2007, American journal of physiology. Lung cellular and molecular physiology.

[41]  S. N. Murthy,et al.  Intratracheal mesenchymal stem cell administration attenuates monocrotaline-induced pulmonary hypertension and endothelial dysfunction. , 2007, American journal of physiology. Heart and circulatory physiology.

[42]  P. Vallance,et al.  Disruption of methylarginine metabolism impairs vascular homeostasis , 2007, Nature Medicine.

[43]  Raed A Dweik,et al.  Alterations of cellular bioenergetics in pulmonary artery endothelial cells , 2007, Proceedings of the National Academy of Sciences.

[44]  Ahmad Y. Sheikh,et al.  Pulmonary arterial hypertension is linked to insulin resistance and reversed by peroxisome proliferator-activated receptor-gamma activation. , 2007, Circulation.

[45]  B. Cochran,et al.  5-HT Induction of c-fos gene expression requires reactive oxygen species and rac1 and ras GTPases , 2007, Cell Biochemistry and Biophysics.

[46]  K. Chin,et al.  Is methamphetamine use associated with idiopathic pulmonary arterial hypertension? , 2006, Chest.

[47]  M. Humbert,et al.  Angiopoietin/Tie2 pathway influences smooth muscle hyperplasia in idiopathic pulmonary hypertension. , 2006, American journal of respiratory and critical care medicine.

[48]  I. Fantozzi,et al.  Bone Morphogenetic Protein-2 Upregulates Expression and Function of Voltage-gated K + Channels in Human Pulmonary Artery Smooth Muscle Cells , 2022 .

[49]  D. McKean,et al.  Tenascin-C is induced by mutated BMP type II receptors in familial forms of pulmonary arterial hypertension. , 2006, American journal of physiology. Lung cellular and molecular physiology.

[50]  S. Archer,et al.  An Abnormal Mitochondrial–Hypoxia Inducible Factor-1&agr;–Kv Channel Pathway Disrupts Oxygen Sensing and Triggers Pulmonary Arterial Hypertension in Fawn Hooded Rats: Similarities to Human Pulmonary Arterial Hypertension , 2006, Circulation.

[51]  M. Hamon,et al.  Transgenic Mice Overexpressing the 5-Hydroxytryptamine Transporter Gene in Smooth Muscle Develop Pulmonary Hypertension , 2006, Circulation research.

[52]  J. Tamargo,et al.  Serotonin Inhibits Voltage-Gated K+ Currents in Pulmonary Artery Smooth Muscle Cells: Role of 5-HT2A Receptors, Caveolin-1, and KV1.5 Channel Internalization , 2006, Circulation research.

[53]  N. Rudarakanchana,et al.  Serotonin Increases Susceptibility to Pulmonary Hypertension in BMPR2-Deficient Mice , 2006, Circulation research.

[54]  P. Kadowitz,et al.  Inhibition of vascular smooth muscle cell proliferation in vitro by genetically engineered marrow stromal cells secreting calcitonin gene-related peptide. , 2006, Life sciences.

[55]  D. Stewart,et al.  Bone Morphogenetic Protein Receptor-2 Signaling Promotes Pulmonary Arterial Endothelial Cell Survival: Implications for Loss-of-Function Mutations in the Pathogenesis of Pulmonary Hypertension , 2006, Circulation research.

[56]  M. Frid,et al.  Hypoxia-induced pulmonary vascular remodeling requires recruitment of circulating mesenchymal precursors of a monocyte/macrophage lineage. , 2006, The American journal of pathology.

[57]  W. Seeger,et al.  Reversal of experimental pulmonary hypertension by PDGF inhibition. , 2005, The Journal of clinical investigation.

[58]  W. Seeger,et al.  Imatinib for the treatment of pulmonary arterial hypertension. , 2005, The New England journal of medicine.

[59]  A. Harmar,et al.  Interdependent Serotonin Transporter and Receptor Pathways Regulate S100A4/Mts1, a Gene Associated With Pulmonary Vascular Disease , 2005, Circulation research.

[60]  J. Loscalzo,et al.  Increased Susceptibility to Pulmonary Hypertension in Heterozygous BMPR2-Mutant Mice , 2005, Circulation.

[61]  P. Jones,et al.  Epidermal Growth Factor Receptor Blockade Mediates Smooth Muscle Cell Apoptosis and Improves Survival in Rats With Pulmonary Hypertension , 2005, Circulation.

[62]  S. Archer,et al.  Gene therapy targeting survivin selectively induces pulmonary vascular apoptosis and reverses pulmonary arterial hypertension. , 2005, The Journal of clinical investigation.

[63]  D. Stewart,et al.  Rescue of Monocrotaline-Induced Pulmonary Arterial Hypertension Using Bone Marrow–Derived Endothelial-Like Progenitor Cells: Efficacy of Combined Cell and eNOS Gene Therapy in Established Disease , 2005, Circulation research.

[64]  Xi C. He,et al.  Bridging the BMP and Wnt Pathways by PI3 Kinase/Akt and 14-3-3? , 2005, Cell cycle.

[65]  R. Trembath,et al.  BMP4 inhibits proliferation and promotes myocyte differentiation of lung fibroblasts via Smad1 and JNK pathways. , 2005, American journal of physiology. Lung cellular and molecular physiology.

[66]  Richard G. W. Anderson,et al.  Low density lipoprotein receptor-related protein 1 (LRP1) controls endocytosis and c-CBL-mediated ubiquitination of the platelet-derived growth factor receptor beta (PDGFR beta). , 2005, The Journal of biological chemistry.

[67]  K. Miyazono,et al.  BMPR-II heterozygous mice have mild pulmonary hypertension and an impaired pulmonary vascular remodeling response to prolonged hypoxia. , 2004, American journal of physiology. Lung cellular and molecular physiology.

[68]  S. Hazen,et al.  Increased arginase II and decreased NO synthesis in endothelial cells of patients with pulmonary arterial hypertension , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[69]  J. Hertzberg,et al.  Extraction of Pulmonary Vascular Compliance, Pulmonary Vascular Resistance, and Right Ventricular Work From Single-Pressure and Doppler Flow Measurements in Children With Pulmonary Hypertension: a New Method for Evaluating Reactivity: In Vitro and Clinical Studies , 2004, Circulation.

[70]  J. Dyck,et al.  Dichloroacetate Prevents and Reverses Pulmonary Hypertension by Inducing Pulmonary Artery Smooth Muscle Cell Apoptosis , 2004, Circulation research.

[71]  J. Knowles,et al.  BMPR2 mutations in pulmonary arterial hypertension with congenital heart disease , 2004, European Respiratory Journal.

[72]  A. Harmar,et al.  Overexpression of the 5-Hydroxytryptamine Transporter Gene: Effect on Pulmonary Hemodynamics and Hypoxia-Induced Pulmonary Hypertension , 2004, Circulation.

[73]  M. Humbert,et al.  Endoglin germline mutation in a patient with hereditary haemorrhagic telangiectasia and dexfenfluramine associated pulmonary arterial hypertension , 2004, Thorax.

[74]  R. Tuder,et al.  Pulmonary Hypertension in Transgenic Mice Expressing a Dominant-Negative BMPRII Gene in Smooth Muscle , 2004, Circulation research.

[75]  M. Frid,et al.  Hypoxia-induced pulmonary artery adventitial remodeling and neovascularization: contribution of progenitor cells. , 2004, American journal of physiology. Lung cellular and molecular physiology.

[76]  K. Kaibuchi,et al.  Long-Term Treatment With a Rho-Kinase Inhibitor Improves Monocrotaline-Induced Fatal Pulmonary Hypertension in Rats , 2004, Circulation research.

[77]  N. Ambartsumian,et al.  S100A4/Mts1 produces murine pulmonary artery changes resembling plexogenic arteriopathy and is increased in human plexogenic arteriopathy. , 2004, The American journal of pathology.

[78]  R. Trembath,et al.  Molecular and functional analysis identifies ALK-1 as the predominant cause of pulmonary hypertension related to hereditary haemorrhagic telangiectasia , 2003, Journal of medical genetics.

[79]  E. Fadel,et al.  Polymorphism of the Serotonin Transporter Gene and Pulmonary Hypertension in Chronic Obstructive Pulmonary Disease , 2003, Circulation.

[80]  K. Brown,et al.  Expression of human herpesvirus 8 in primary pulmonary hypertension. , 2003, The New England journal of medicine.

[81]  M. Goumans,et al.  Stimulation of Id1 Expression by Bone Morphogenetic Protein Is Sufficient and Necessary for Bone Morphogenetic Protein–Induced Activation of Endothelial Cells , 2002, Circulation.

[82]  S. Hodge,et al.  BMPR2 germline mutations in pulmonary hypertension associated with fenfluramine derivatives , 2002, European Respiratory Journal.

[83]  S. Kihara,et al.  Adipocyte-Derived Plasma Protein Adiponectin Acts as a Platelet-Derived Growth Factor-BB–Binding Protein and Regulates Growth Factor–Induced Common Postreceptor Signal in Vascular Smooth Muscle Cell , 2002, Circulation.

[84]  N. Rudarakanchana,et al.  Functional analysis of bone morphogenetic protein type II receptor mutations underlying primary pulmonary hypertension. , 2002, Human molecular genetics.

[85]  M. Frid,et al.  Mature Vascular Endothelium Can Give Rise to Smooth Muscle Cells via Endothelial-Mesenchymal Transdifferentiation: In Vitro Analysis , 2002, Circulation research.

[86]  R. Trembath,et al.  Primary Pulmonary Hypertension Is Associated With Reduced Pulmonary Vascular Expression of Type II Bone Morphogenetic Protein Receptor , 2002, Circulation.

[87]  J. Stewart,et al.  A bradykinin antagonist and a caspase inhibitor prevent severe pulmonary hypertension in a rat model. , 2002, Canadian journal of physiology and pharmacology.

[88]  Anja Nohe,et al.  The Mode of Bone Morphogenetic Protein (BMP) Receptor Oligomerization Determines Different BMP-2 Signaling Pathways* , 2002, The Journal of Biological Chemistry.

[89]  M. Humbert,et al.  CX(3)C chemokine fractalkine in pulmonary arterial hypertension. , 2002, American journal of respiratory and critical care medicine.

[90]  R. Trembath,et al.  Altered Growth Responses of Pulmonary Artery Smooth Muscle Cells From Patients With Primary Pulmonary Hypertension to Transforming Growth Factor-&bgr;1 and Bone Morphogenetic Proteins , 2001, Circulation.

[91]  N. Voelkel,et al.  Microsatellite Instability of Endothelial Cell Growth and Apoptosis Genes Within Plexiform Lesions in Primary Pulmonary Hypertension , 2001, Circulation research.

[92]  S. Hodge,et al.  Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene. , 2000, American journal of human genetics.

[93]  R. Trembath,et al.  Heterozygous germline mutations in BMPR2, encoding a TGF-β receptor, cause familial primary pulmonary hypertension , 2000, Nature Genetics.

[94]  T. L. Le Cras,et al.  Early abnormalities of pulmonary vascular development in the Fawn-Hooded rat raised at Denver's altitude. , 2000, American journal of physiology. Lung cellular and molecular physiology.

[95]  K. Lesch,et al.  Attenuated hypoxic pulmonary hypertension in mice lacking the 5-hydroxytryptamine transporter gene. , 2000, The Journal of clinical investigation.

[96]  Adrian M Heilbut,et al.  Complete reversal of fatal pulmonary hypertension in rats by a serine elastase inhibitor , 2000, Nature Medicine.

[97]  M. Humbert,et al.  Pulmonary hypertension related to drugs and toxins. , 1999, Current opinion in cardiology.

[98]  P. Jones,et al.  Regulation of Tenascin-C, a Vascular Smooth Muscle Cell Survival Factor that Interacts with the αvβ3 Integrin to Promote Epidermal Growth Factor Receptor Phosphorylation and Growth , 1997, The Journal of cell biology.

[99]  P. Jones,et al.  Tenascin-C, proliferation and subendothelial fibronectin in progressive pulmonary vascular disease. , 1997, The American journal of pathology.

[100]  G. Sinha,et al.  Primary pulmonary hypertension in HIV infection: an outcome determined by particular HLA class II alleles. , 1996, American journal of respiratory and critical care medicine.

[101]  M. Rabinovitch,et al.  Exogenous leukocyte and endogenous elastases can mediate mitogenic activity in pulmonary artery smooth muscle cells by release of extracellular matrix‐bound basic fibroblast growth factor , 1996, Journal of cellular physiology.

[102]  V. S. Zhdanov,et al.  Pulmonary artery adventitial changes and venous involvement in primary pulmonary hypertension. , 1995, The American journal of pathology.

[103]  R. Mecham,et al.  Neointimal macrophages colocalize with extracellular matrix gene expression in human atherosclerotic pulmonary arteries. , 1993, The Journal of clinical investigation.

[104]  A. Tucker,et al.  Acute and long-term TNF-alpha administration increases pulmonary vascular reactivity in isolated rat lungs. , 1992, Journal of applied physiology.

[105]  L. McCready,et al.  Increased pulmonary artery elastolytic activity in adult rats with monocrotaline-induced progressive hypertensive pulmonary vascular disease compared with infant rats with nonprogressive disease. , 1992, The American review of respiratory disease.

[106]  M. Rabinovitch,et al.  Chronic hypoxic pulmonary hypertension in rats and increased elastolytic activity. , 1991, The American journal of physiology.

[107]  M. Rabinovitch,et al.  Inhibition of elastolysis by SC-37698 reduces development and progression of monocrotaline pulmonary hypertension. , 1991, The American journal of physiology.

[108]  M. Rabinovitch,et al.  Endothelial injury and vascular reactivity in monocrotaline pulmonary hypertension. , 1988, The American journal of physiology.

[109]  W. Williams,et al.  Pulmonary artery endothelial abnormalities in patients with congenital heart defects and pulmonary hypertension. A correlation of light with scanning electron microscopy and transmission electron microscopy. , 1986, Laboratory investigation; a journal of technical methods and pathology.

[110]  S. Clarke,et al.  Primary pulmonary hypertension: a case report including electronmicroscopic study. , 1974, British journal of diseases of the chest.

[111]  J. Axelrod,et al.  Bone morphogenetic protein 2 induces pulmonary angiogenesis via Wnt –-catenin and Wnt – RhoA – Rac 1 pathways , 2022 .